CEL:LSE Celadon Pharmaceuticals PLC

GBX 61.00 1.50 2.521008
Icon

Celadon Pharmaceuticals PLC (CEL:LSE) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | LSE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

GBX 61.00

+1.50 (+2.52)%

GBX 0.04B

0.01M

N/A

N/A

Icon

CEL:LSE

Celadon Pharmaceuticals PLC (GBX)
COMMON STOCK | LSE
GBX 61.00
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

GBX 0.04B

N/A

GBX 61.00

Celadon Pharmaceuticals PLC (CEL:LSE) Stock Forecast

N/A

Based on the Celadon Pharmaceuticals PLC stock forecast from 0 analysts, the average analyst target price for Celadon Pharmaceuticals PLC is not available over the next 12 months. Celadon Pharmaceuticals PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Celadon Pharmaceuticals PLC is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Celadon Pharmaceuticals PLC’s stock price was GBX 61.00. Celadon Pharmaceuticals PLC’s stock price has changed by +0.83% over the past week, -17.57% over the past month and -59.33% over the last year.

No recent analyst target price found for Celadon Pharmaceuticals PLC
No recent average analyst rating found for Celadon Pharmaceuticals PLC

Company Overview Celadon Pharmaceuticals PLC

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spe...Read More

https://celadonpharma.com/

32-33 Cowcross Street, London, United Kingdom, EC1M 6DF

27

December

GBX

UK

Adjusted Closing Price for Celadon Pharmaceuticals PLC (CEL:LSE)

Loading...

Unadjusted Closing Price for Celadon Pharmaceuticals PLC (CEL:LSE)

Loading...

Share Trading Volume for Celadon Pharmaceuticals PLC Shares

Loading...

Compare Performance of Celadon Pharmaceuticals PLC Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CEL:LSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Celadon Pharmaceuticals PLC (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HLN:LSE
Haleon PLC +0.50 (+0.15%) GBX31.12B 28.40 16.14

ETFs Containing CEL

Symbol Name CEL's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Celadon Pharmaceuticals PLC (CEL:LSE) Stock

Stock Target Advisor's fundamental analysis for Celadon Pharmaceuticals PLC's stock is Bearish.

Unfortunately we do not have enough data on CEL:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on CEL:LSE's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on CEL:LSE's stock to indicate if its overvalued.

The last closing price of CEL:LSE's stock was GBX 61.00.

The most recent market capitalization for CEL:LSE is GBX 0.04B.

Unfortunately we do not have enough analyst data on CEL:LSE's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Celadon Pharmaceuticals PLC's stock.

As per our most recent records Celadon Pharmaceuticals PLC has 27 Employees.

Celadon Pharmaceuticals PLC's registered address is 32-33 Cowcross Street, London, United Kingdom, EC1M 6DF. You can get more information about it from Celadon Pharmaceuticals PLC's website at https://celadonpharma.com/.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...